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Introduction: Human Wharton’s jelly (WJ) has become a preferred source of mesenchymal stem cells (MSCs)
whose clinical applications are limited by the use of adequate xeno-free (XF), in vitro manipulation conditions.
Therefore, the objective of our study was to characterize WJ-derived MSCs (WJ-MSCs), isolated by different methods
and cultured in a commercially available, MSC XF medium, not least of all by investigating their endothelial
differentiation capacity.
Methods: WJ explants and enzymatically dissociated WJ cells were cultured in a defined, XF medium for MSCs.
Adherent cells at passages 2 and 5 were characterized as MSCs by flow cytometry, MTT, real-time quantitative reverse
transcription PCR, and functional multipotent differentiation assays. The endothelial differentiation capacity of MSCs
isolated and expanded until passage 2 in the MSC XF medium, and then subcultured for five passages
in a commercially available endothelial growth medium (group A), was assessed over serial passages, as compared to
adherent WJ-derived cells isolated and expanded for five consecutive passages in the endothelial medium (group B).
Results: The MSC phenotype of WJ explant- and pellet-derived cells, isolated and expanded in the MSC XF medium,
was proven based on the expression of CD44/CD73/CD90/CD105 surface markers and osteo-/adipo-/chondrogenic
multipotent differentiation potential, which differed according to the isolation method and/or passage number. Upon
exposure to endothelial differentiation cues, cells belonging to group A did not exhibit endothelial cell characteristics
over serial passages; by contrast, WJ pellet-derived cells belonging to group B expressed endothelial characteristics at
gene, protein and functional levels, potentially due to culture conditions favoring the isolation of other stem/progenitor
cell types than MSCs, able to give rise to an endothelial progeny.
Conclusions: The use of defined, MSC XF media for isolation and expansion of human WJ-MSCs is a prerequisite for
the establishment of their real endothelial differentiation capacity, as candidates for clinical therapy applications. Thus,
the standardization of WJ-MSCs isolation and culture expansion techniques in defined, MSC XF media, for their accurate
characterization, would be a priority in the stem cell research field.
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Among multiple sources of stem cells, human umbilical
cord matrix, namely, Wharton’s jelly (WJ), has recently
become the preferential source of stem cells, including
mesenchymal stem cells (MSCs), because of rapid avail-
ability with a large donor pool, non-invasive collection
with no risk or discomfort for the donor, no ethical con-
straints, high in vitro expandable rates and multipotent
differentiation potential [1-7]. Due to proven immuno-
modulatory effects, WJ-derived MSCs (WJ-MSCs) are
now considered attractive agents not only for autolo-
gous, but also for allogeneic cell therapy approaches of
malignant and non-malignant, hematopoietic and non-
hematopoietic, inherited and acquired diseases [1,8,9].
Whereas adult bone marrow (BM)-derived MSCs
(BM-MSCs) have shown limited therapeutic benefits
for organ regeneration, it has been postulated that WJ-
derived primitive stromal cells are a valuable alternative
source of cells that possess multipotent properties
between embryonic and adult stem cells [2,10-12]. WJ-
MSCs have a higher proliferation rate [13,14] and a
higher expression level of early endodermal markers,
as well as undifferentiated human embryonic and pluri-
potent/stem cell markers, both at early and late pas-
sages [12]. Although WJ-MSCs share common surface
markers with BM-MSCs, such as the immunomodula-
tory molecules [4,15], they are endowed with superior
plasticity properties [3]. Furthermore, it has been shown
that the immune privilege exerted by WJ-MSCs is also
maintained in the differentiated adipogenic, osteogenic
and chondrogenic progeny [5].
Generation of an endothelial cell outgrowth from
the matrix of the umbilical cord, for vascular regener-
ation purposes, has been described by several groups
[13,16-19]; however, the applied differentiation proto-
cols did not involve the use of a defined MSC medium
for WJ-MSCs isolation prior to their seeding into endo-
thelial differentiation media, raising the question of po-
tential contamination of the generated cultures with
other stem cell types able to give rise to an endothelial
progeny, circulating endothelial progenitor cells or ma-
ture endothelial cells.
Several groups have established various protocols for
the isolation and characterization of stromal cells from
WJ [11,18,20-23]. However, the effects of defined, xeno-
free (XF) media, designed for MSCs isolation and expan-
sion, on the gene, protein and functional profiles of
WJ-MSCs have not been thoroughly investigated. It has
been shown that XF culture systems allow for better
multipotent differentiation and/or expansion rates of
adipose tissue- and BM-MSCs, serving as a preferred
alternative to fetal bovine serum (FBS)-containing media
for the production of large scale, functionally competent,
clinical grade MSCs [24-26]. In addition, the use of FBSfor MSCs in vitro isolation and expansion raises con-
cerns for the transmission of zoonoses and induction of
immunogenic reactions after clinical transplantation,
due to xenogeneic proteins transmitted from FBS to
MSCs during culture [27,28]. Therefore, the in vitro
manipulation of MSCs by using XF culture conditions
before clinical applications has become an important
step in order to yield homogenous cell populations with
self-renewal and multi-lineage differentiation potential,
but without an increase in chromosome aberrations.
Despite a wide range of potential clinical applications,
such as for bone [29], cartilage [30], musculoskeletal
[31,32] and nerve [33] regeneration, for the treatment of
liver fibrosis [10,34] and type 1 diabetes [35], as well as
for heart valve [36] and vocal fold reconstruction [37],
WJ-MSC populations isolated in defined, XF conditions
have not been fully characterized. Therefore, given their
particular plasticity and developmental flexibility, the
impact of XF conditions on functional properties of umbil-
ical cord stromal cells deserve to be thoroughly examined.
To elucidate the real value of WJ-MSCs for clinical cell re-
placement therapy, further work is thus needed in order
to determine whether these cells, isolated and expanded in
defined, XF media, truly express differentiation capabilities
beyond the canonical plasticity towards the adipogenic,
osteogenic and chondrogenic cell lineages [38].
To get further insights into the biology of WJ-derived
cells, the objectives of our study were to isolate, by using
different protocols, and expand human WJ-MSCs in a
commercially available, XF medium, selective for MSCs,
and to characterize them at gene, protein and functional




Human umbilical cord samples were collected following
term deliveries at the Department of Obstetrics and
Gynecology, “Dr. I. Cantacuzino” Hospital, Bucharest,
Romania. The samples were obtained upon written
informed consent from mothers and complied with
European Union and national legislation regarding hu-
man samples collection, manipulation and personal
data protection. All samples were tested for the absence
of HIV, HBV and HCV and processed within three
hours of collection.
WJ was isolated from the umbilical cords after dissec-
tion and removal of the umbilical cord arteries, vein and
amniotic epithelium. MSCs isolation from WJ was
achieved either by mechanical dissociation for gener-
ation of tissue explants of approximately 2 mm2, or by
enzymatic dissociation with collagenase I and hyaluroni-
dase (Sigma-Aldrich, St. Louis, MO, USA) for generation
of WJ cell pellets. Tissue explants and suspended cell
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(10 tissue explants/dish) and flasks (5 × 105 cells/flask),
respectively, pre-coated with MesenCult™-XF Attach-
ment Substrate, in MesenCult™-XF Complete medium
(XF medium), consisting of MesenCult™-XF Basal
medium supplemented with 20% MesenCult™-XF Prolif-
eration Supplement (all from STEMCELL Technologies™
Inc., Vancouver, BC, Canada), L-Glutamine to a final
concentration of 2 mM, 100 U/ml penicillin, 100 μg/ml
streptomycin and 50 μg/ml neomycin (all from Sigma-
Aldrich). Cultures of both WJ tissue explants and
suspended cell pellets were maintained at 37°C with
5% CO2 and 21% O2 in a humidified atmosphere. For
optimal cell growth, medium was changed at the
moment of subculture or, if the medium appeared acidic
prior to cells reaching 80% confluence, half-medium
change was performed. For the purpose of subculturing,
the cells were enzymatically-detached using the MesenCult™
Dissociation Kit (STEMCELL Technologies™ Inc.). Cells
from passages (P) 2 and 5 were used for cell characterization
experiments (see Figure 1 describing the experimental
design). Five WJ explant-derived and eight WJ pellet-
derived MSC populations were isolated and expanded
in the XF medium until P5 for the proposed experi-
ments. All procedures were approved by the Ethical
Committee Board of the Institute of Cellular Biology
and Pathology “Nicolae Simionescu”, Bucharest.
Cells characterization
Proliferation assays
Morphological characterization of cells was done by light
microscopy, using an inverted epifluorescence microscopeFigure 1 Experimental design. Isolation and expansion of MSCs, derived
defined for MSCs, followed by their characterization, not the least by invest
endothelial differentiation capacity (at P2, as compared to WJ-derived cells
different clinical settings of regenerative and reconstructive medicine [13,1
cord; WJ, Wharton’s jelly; XF, xeno-free.(Eclipse TE300, Nikon, Tokyo, Japan) and a digital camera
system for imaging (Digital Net Camera DN100, Nikon).
Viability and proliferation of WJ explant- and pellet-
derived MSC populations (n = 5) at P2 were evaluated
using a modified colorimetric 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay method
(CellTiter96 Non-Radioactive Cell Proliferation Assay,
Promega, Madison, WI, USA), according to the manufac-
turer’s instructions. Cells were seeded in 96-well plates at
a density of 3 × 103 cells/well in the XF medium. The
assay was performed every 24 hours during a two-week
period, in triplicates. The absorbance was measured at a
wavelength of 570 nm by using a spectrophotometric
plate reader (Mithras LB 940, Berthold Technology, Bad
Wildbad, Germany).
Adipogenesis, osteogenesis and chondrogenesis assays
In vitro differentiation potential of WJ explant- and pellet-
derived MSC populations (n = 5) at P2 and P5 into
adipogenic, osteogenic and chondrogenic lineages was
assessed by using specifically formulated cell culture media
(MesenCult™ Adipogenic Stimulatory Supplements-Human
and MesenCult™ Osteogenic Stimulatory Kit-Human from
STEMCELL Technologies™ Inc., as well as StemMACS
ChondroDiff Media-Human from Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany), and the manufacturer’s
guidelines.
Briefly, for adipocyte and osteocyte differentiation,
MSCs were plated at a density of 12.5 × 103 cells/cm2
and 5 × 103 cells/cm2, respectively, in six-well cell cul-
ture plates and kept in normoxic conditions for two and
four weeks, respectively, with medium changed everyfrom WJ explants and enzymatically dissociated WJ, in a XF medium
igating their osteogenic, chondrogenic, adipogenic (at P2 and P5) and
expanded from P0 in endothelial differentiation conditions), for use in
6-19,29,30,39]. MSCs, mesenchymal stem cells; P, passage; UC, umbilical
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staining with Oil Red O (0.5% in isopropanol) and osteo-
genic differentiation was visualized by Alizarin Red S
(2% in distilled water) staining (both from Sigma-
Aldrich). To these purposes, cells were fixed with a 4%
paraformaldehyde solution in 1x phosphate-buffered
saline (PBS) for 30 minutes at room temperature; for
Oil Red staining only, cells were washed with distilled
water and 60% isopropanol. Cells were thereafter
maintained with the corresponding staining for five mi-
nutes, rinsed with distilled water three times to remove
excess stain, and then photographed by using an
inverted microscope (Eclipse TE300, Nikon) and a
digital camera system for imaging (Digital Net Camera
DN100, Nikon).
For chondrogenic differentiation, 2.5 × 105 cells were
centrifuged (150 × g, five minutes) at room temperature.
The resulting cell pellets were cultured for 24 days in
15 ml polystyrene centrifugation tubes in differenti-
ation medium, with medium changed every 3 days. The
resulting nodular cell clusters were embedded in paraf-
fin (Carl Roth GmbH, Karlsruhe, Germany) and 10-
μm-thick sections were stained with Alcian Blue (1% in
30% acetic acid) and Toluidine Blue O (both from
Sigma-Aldrich) for 30 and 2 minutes, respectively, for
chondrogenic extra-cellular matrix containing hyalur-
onic acids. Briefly, the stained preparations were
washed in running water for two minutes, rinsed in dis-
tilled water, dehydrated in graded ethanol series, followed
by three clarification steps in xylene and mounting. The
cover-slipped slides were then photographed by using an
inverted microscope (Eclipse TE300, Nikon) and a digital
camera system for imaging (Digital Net Camera DN100,
Nikon). The negative controls were represented by corre-
sponding MSCs at P5 not cultured into differentiation
media.
Endothelial differentiation assays
For the purpose of testing the true endothelial differenti-
ation potential of WJ explant- and pellet-derived MSCs,
isolated in a highly selective medium for MSCs, we
conducted parallel endothelial differentiation assays,
by using two cell groups (A and B). Cells from group A
(n = 5) were either explant- or pellet-derived MSCs iso-
lated and expanded in the XF medium until P2, and
thereafter exposed to endothelial differentiation condi-
tions for five consecutive passages. Cells from group B
(n = 5) consisted of adherent cells resulted from either
WJ-derived explants or pellets, directly cultured from P0
to P5 in endothelial differentiation conditions. The proto-
cols applied for WJ isolation and mechanical/enzymatic
dissociation, as well as for endothelial differentiation, were
identical for both cell groups.Endothelial differentiation conditions consisted of
explants/cells seeding onto culture flasks pre-coated
with 2 μg/cm2 fibronectin (BD Biosciences, San Jose,
CA, USA), in Endothelial Cell Growth Medium MV2
(Promocell, Heidelberg, Germany), supplemented with
20% FBS and 40 ng/ml vascular endothelial growth fac-
tor (VEGF). The cells were kept in normoxic conditions
in a humidified atmosphere for five serial passages.
Endothelial differentiation was assessed by morphology,
flow cytometry, qualitative reverse transcription (RT)
polymerase chain reaction (PCR) and real-time quantita-
tive RT-PCR (qRT-PCR), as well as Matrigel tube forma-
tion assay.
Flow cytometry analysis
Expression of cell surface molecules on WJ explant- and
pellet-derived MSCs at P2 and P5 (n = 5) cultured in the
XF medium was assessed by using a FACSCalibur in-
strument (BD, Franklin Lakes, NJ, USA). Surface marker
expression on WJ explant- and pellet-derived cells cul-
tured in endothelial differentiation conditions for five
passages (groups A and B, n = 5 for each group) was
analyzed by using a MoFlo FACS instrument (Dako,
Glostrup, Denmark). The controls were represented by
enzymatically dissociated, freshly isolated WJ cells (n = 3)
and a NUFF1 human fibroblast cell line. To this pur-
pose, 1 × 105 cells were stained with fluorochrome-
conjugated (either phycoerythrin (PE) or fluorescein
isothiocyanate (FITC)) antibodies against CD31, CD34,
CD44, CD45, CD73, CD90, CD105, CD144 and CD309
(VEGF receptor (VEGFR) 2) antibodies (MACS,
Miltenyi Biotec). Enzymatically-detached cells, using
the MesenCult™ Dissociation Kit (STEMCELL Tech-
nologies™ Inc.) for MSCs and accutase (Sigma-Aldrich)
for cells cultured in the endothelial differentiation
medium, were washed in 1× PBS containing 2% FBS
and incubated for 30 minutes at 4°C with the appropri-
ate diluted FITC-/PE-conjugated antibodies (1:100 dilu-
tion for CD90 antibody and 1:50 dilution for the rest of
antibodies, in 1× PBS containing 2% FBS). For isotype
control, the cells were stained with 1:50 diluted
isotype-matched IgG (IgG1, MACS, MiltenyiBiotec).
Ten thousand cells were acquired from each sample
and flow cytometry data were analyzed using either the
CellQuest Pro (BD) or Summit 4.0 (Dako) softwares,
according to the instrument used. Median fluorescence
intensity (MFI) was measured for each surface marker
and background values were subtracted to obtain
ΔMFI.
RT-PCR and qRT-PCR
Molecular characterization of cells used in differenti-
ation assays was done by RT-PCR and qRT-PCR. For
qRT-PCR, total RNA was extracted with the PureLink™
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First-strand cDNA synthesis was performed on 1 μg of
total RNA; cDNA samples were thereafter amplified in
triplicates by using a real-time PCR system (Applied
Biosystems 7900HT Fast, Life Technologies™) for 40 cy-
cles (95°C for 2 minutes, 95°C for 5 sec, 60°C for 10 sec,
72°C for 15 sec, plus a dissociation cycle at 95°C for 15
sec and 60°C for 15 sec) with specific oligonucleotide
primers (Applied Biosystems-Life Technologies™, Carlsbad,
CA, USA) to assess quantitative mRNA expression for
osteocalcin, aggrecan, CD31, von Willebrand factor (vWF)
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as
endogenous control. WJ-MSCs not used into differentiation
assays and enzymatically dissociated, freshly isolated WJ cells
were used as controls; qRT-PCR data were analyzed
by using the SDS 2.4 Standalone software (Applied
Biosystems-Life Technologies™). For RT-PCR, total
RNA was extracted with the GenElute™ Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich). First-strand
cDNA synthesis was performed on 1 μg of total RNA;
cDNA samples were thereafter amplified in a
thermocycler (Bio-Rad Laboratories, Hercules, CA,
USA) for 35 cycles (94°C for 45 sec, 60°C for 45 sec
and 72°C for 45 sec) with specific oligonucleotide
primers (Metabion, Martinsried, Germany) to assess
mRNA expression for CD31, CD34, CD144, VEGFR1,
VEGFR2, vWF, GATA2, Tie-2 and GAPDH, as endogen-
ous control. Enzymatically dissociated, freshly isolated
WJ cells and a human umbilical vein endothelial cell
(HUVEC) line (Promocell) were used as controls. The
oligonucleotide primer sequences for both RT-PCR and
qRT-PCR are shown in Table 1.
Matrigel assay
Matrigel assay was performed by using 50 μl of Matrigel
Basement Membrane Matrix (BD Biosciences) added to
48-well plates; the Matrigel was allowed to solidify at
37°C for 30 minutes and 5 × 104 cells were, thereafter,
suspended in 100 μl Endothelial Cell Growth Medium
MV2 (Promocell), supplemented with 20% FBS and 40
ng/ml VEGF, and plated onto the Matrigel layer. A
HUVEC line (Promocell) was used as a positive control.
After 24 hours, the medium was removed and the for-
mation of vascular tube-like structures was assessed with
an inverted microscope (Eclipse TS100, Nikon) and a
digital camera system for imaging (Digital SLR Camera
D300, Nikon).
Statistical analyses
Statistical analyses were performed either by a one-way
analysis of variance (ANOVA) with the Microcal
OriginPro - version 6.0 software (OriginLab Corporation,
Northampton, MA, USA) or by a two-tailed unpaired t
test with the GraphPad Prism 4 software (GraphPadSoftware, Inc., La Jolla, CA, USA). The results were
presented as mean ± standard error of the mean and
differences were considered statistically significant when
P-value < 0.05.
Results
WJ mesenchymal-like cells highly proliferate in the XF
medium
In order to test whether the XF medium is suitable for
WJ-MSCs isolation and expansion, we isolated WJ cells
using two different approaches, either from WJ explants
or enzymatically dissociated WJ cells. Our results dem-
onstrated that primary cultures of adherent cells, with a
mesenchymal-like morphology, grew in colonies out of
the WJ explants (Figure 2.A.1a, 1b) and were subcultured,
on average, at 14 days after plating, whereas adherent cells
resulting from culture of suspended WJ-derived pellets
(Figure 2.A.2a, 2b) reached 80% confluence and were
subcultured, on average, at 10 days after plating. Both ex-
plant and pellet-derived cells maintained their morphology
after subsequent subculturing (Figure 2.B.3a, 3b and 4a,
4b, respectively). Furthermore, both cell population types
presented a high proliferation rate, which doubled every
24 hours (P < 0.05) during the first week of assessment
(Figure 2.C). Thus, the XF medium was suitable for the
isolation of both WJ explant- and pellet-derived adherent
cells with a mesenchymal-like phenotype and a high pro-
liferation rate.
WJ-derived cells cultured in the XF medium presented
MSC characteristics
For the purpose of testing if the XF medium could lead
to the isolation and expansion of cells with true MSC
characteristics, we assessed their functional ability to dif-
ferentiate into adipogenic, osteogenic and chondrogenic
lineages, as well as the presence of MSC molecules at
gene and protein levels. The cyto/histochemical staining
of in vitro differentiation assay preparations revealed
that, under specific culture conditions, both WJ explant-
and pellet-derived MSCs, isolated and expanded in the
XF medium, presented adipogenic, osteogenic and
chondrogenic differentiation capacity (Figure 3.I.A, I.B),
as compared to controls represented by WJ explant (data
not shown) and pellet-derived MSCs (Figure 3.I.C) not
cultured in differentiation media that did not show
three-lineage differentiation potential. In respect to the
degree of adipogenic differentiation, accumulation of
lipid droplets was more robust in WJ pellet-derived
MSCs at P5, as compared to WJ pellet-derived MSCs at
P2 and WJ explant-derived MSCs (Figure 3.II.A, II.B).
Furthermore, quantitative gene expression of osteocalcin
and aggrecan, involved in MSCs differentiation into osteo-
genic and chondrogenic lineages, respectively, significantly
increased (P < 0.05) in explant-derived MSCs, as compared
Table 1 Sequences of the oligonucleotide primers used for qRT-PCR and RT-PCR
Gene GeneBank® accession number Sequences of oligonucleotide primers Predicted size (bp)
qRT-PCR
vVF [NM_000552.3] S: 5′-CGACATGGAGGATGCCGT-3′ 236
A: 5′-ACTCATTGATGAGGCAGGGGT-3′
CD31 [NM_000442.4] S: 5′-CTGCTGACCCTTCTGCTCTG-3′ 203
A: 5′-TAAAACAGCACGTCATCCTTATAGA-3′
GAPDH [NM_002046] S: 5′-TTGGTATCGTGGAAGGACTCA-3′ 270
A: 5′-TGTCATCATATTTGGCAGGTTT-3′
Aggrecan [NM_001135.3] S: 5′-GTGCCTATCAGGACAAGGTCT-3′ 167
A: 5′-GATGCCTTTCACCACGACTTC-3
Osteocalcin [NM_199173.4] S: 5′-GCCCTCACACTCCTCGCCCTA-3′ 100
A: 5′-AGGCTGCACCTTTGCTGGACTC-3
GAPDH [NM_001256799.1] S: 5′-TTGGTATCGTGGAAGGACTCA-3′ 267
A: 5′-TGTCATATTTGGCAGGTTT-3
RT-PCR
CD31 [NM_000442] S: 5′-AGCACCACCTCTCACGTCA-3′ 250
A: 5′-CTTGGATGGCCTCTTTCTTG-3′
CD144 [NM_001795] S: 5′-CCTTGGGATAGCAAACTCCA-3′ 283
A: 5′-CTTTGCCTCCAGGCAGATAG-3′
CD34 [NM_001773] S: 5′-TCAGTTCTAGTCTCTCTGGGGC-3′ 328
A: 5′-ATAAGGGTTAGGAGCTGATCTGG-3′
VEGFR1 [NM_002019] S: 5′-CAGCCCATAAATGGTCTTTGCC-3′ 557
A: 5′-TAATTTGACTGGGCGTGGTGTG-3′
VEGFR2 [NM_002253] S: 5′-GTGACCAACATGGAGTCGTG-3′ 660
A: 5′-CCAGAGATTCCATGCCACTT-3′
VWF [NM_000552] S: 5′-CGACTTCCTTACCCCCTCTG-3′ 247
A: 5′-GCAGGAGCACACGTCGTAG-3′
GATA2 [NM_032638] S: 5′-CCCTAAGCAGCGCAGCAAGAC-3′ 439
A: 5′-TGACTTCTCCTGCATGCACT-3′
Tie-2 [NM_000459] S: 5′-CATACTGGGGAAAGCAATGAAAC-3′ 281
A: 5′-ACCACTGTTTTTCACCTTCCAAA-3′
GAPDH [NM_002046] S: 5′-ACCACAGTCCATGCCATCAC-3′ 450
A: 5′-TCCACCACCCTGTTGCTGTA-3′
A, antisense; S, sense.
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pellet-derived MSCs, both aggrecan and osteocalcin gene
expression were significantly increased (P < 0.05) at P2 as
compared to controls, but significantly decreased (P <
0.05) by passage progression (Figure 4.1a, 1b).
In addition, flow cytometry analysis of XF medium
cultured MSCs, derived from both WJ explants and cell
pellets, revealed that the cells were positive, at both P2
(Figure 5.1 and 2, respectively) and P5 (data not shown)
for MSC surface markers such as CD44, CD73, CD90
and CD105, and were negative for hematopoietic stem
cell (CD34) and monocyte-macrophage (CD45) markers;interestingly, enzymatically dissociated, freshly isolated
WJ cells (P0) showed only CD44 surface marker expres-
sion (Figure 6.C). When we compared MFI of MSC
markers between passages, the WJ explant-derived
MSCs had a statistical significantly higher (P < 0.05)
CD73 expression at P5, as compared to P2 (Figure 5.3a).
Furthermore, MSCs derived from WJ cell pellets
exhibited a statistical significantly higher (P < 0.05) ex-
pression of CD44 at P2, as compared to P0 and P5, and
a statistical significantly higher (P < 0.05) expression of
CD73 marker at P2, as compared to P5 (Figure 5.3b).
Moreover, when we compared explant- versus pellet-
Figure 2 Assessment of morphology and proliferation rate of
MSCs isolated and subcultured in XF medium. A. Morphological
evaluation of primary MSC cultures derived fromWJ explants (explant-
MSCs -1a, 1b) and enzymatically dissociatedWJ (pellet-MSCs -2a, 2b);
B.Morphological evaluation of P5 subcultures of WJ explant (3a, 3b)- and
pellet (4a, 4b)-derivedMSCs; highermagnifications of corresponding
pictures are pointed by arrows;C.MTT assay onWJ explant (1)- and pellet
(2)-derivedMSCs at P2; d, day of assessment; *, **, ***, P< 0.05, indicates
statistical significance in cell proliferation during consecutive time points of
assessment (*, Day 3 vs. Day 1; **, Day 5 vs. Day 3; *** days 7, 9, 13 vs. Day 5).
MSCs,mesenchymal stem cells; P, passage;WJ, Wharton’s jelly; XF, xeno-free.
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istical significantly higher MFI for CD44 and CD73
markers (P < 0.005 and P < 0.05, respectively) than the
explant-derived counterparts and a statistical significantly
higher MFI (P < 0.005) for CD44 marker, as opposed to
pellet-derived WJ cells at P0 (Figure 5.3c). Taken together,
the results of in vitro differentiation assays corroborated
with the results of MSC molecules assessment indicated
that both WJ explant- and pellet-derived adherent cells
cultured in the XF medium showed different degrees ofmultipotent differentiation and expression of markers
characteristic for MSCs, according to the isolation method
and/or passage number.
WJ-MSCs cultured in the XF medium did not
subsequently differentiate into endothelial cells
In order to investigate if the WJ-MSCs isolated and
expanded in the XF medium could differentiate into
endothelial cells, we performed endothelial differenti-
ation assays. Upon exposure for five serial passages to
endothelial differentiation medium, both WJ explant-
and cell pellet-derived MSCs isolated and expanded until
P2 in the XF medium (group A), presented a fibroblast-
like morphology (Figure 7.I.A.1a/1b and 3a/3b, respect-
ively) and did not form tube-like structures upon culture
on Matrigel basement membrane matrix (Figure 7.II.A.1
and 4, respectively). By contrast, adherent cells from
group B, isolated and subcultured for five consecutive
passages in endothelial differentiation conditions, de-
rived from WJ cell pellets, developed an epithelial-like
morphology and presented functional characteristics
of endothelial cells by forming vascular tube-like
structures in Matrigel (Figure 7.I.B.4a/4b and II.B.5a/5b,
respectively), while the WJ explant-derived counterparts
maintained a fibroblast-like morphology and did not
exhibit tube-forming characteristics (Figure 7.I.B.2a/2b
and II.B.2, respectively).
Furthermore, flow cytometry analyses indicated that
both explant- and pellet-derived cells belonging to group
A did not express endothelial surface molecules and
maintained the expression of CD44, CD73 and CD90
MSC markers, while losing CD105 marker expression
(Figure 6.A.1 and A.2, respectively); however, WJ pellet-
derived cells showed a statistical significantly higher
(P < 0.05) CD44 expression than freshly isolated WJ-
derived cells (P0) and a statistical significantly higher
(P < 0.05) CD73 expression, as compared to explant-
derived cells (Figure 6.D.a). Within group B, explant-
derived cells also did not show endothelial surface mole-
cules, but expressed CD44, CD73 and CD90 MSC
markers (Figure 6.B.1). Interestingly, the pellet-derived
cells belonging to group B presented a high expression
of CD44 and CD73, but not CD90 markers; furthermore,
they presented an endothelial phenotype through ex-
pression of CD31, CD105 and CD144 surface molecules
(Figure 6.B.2). When we compared MSC markers ex-
pression between groups A and B, the only statistically
significant differences applied to explant-derived cells,
whose CD44 and CD90 expression was higher (P < 0.05
and P = 0.0005, respectively) in group B, as compared to
group A cells (Figure 6.D.b).
Moreover, quantitative gene expression of vWF and
CD31 endothelial markers did not significantly increase
in group A cells, as compared to controls (Figure 4.2a
Figure 3 In vitro differentiation assays of WJ-MSCs at P2/P5,
isolated and expanded in XF medium. I. Representative images of
MSCs, isolated from both WJ explants (explant-MSCs, A) and
enzymatically dissociated WJ (pellet-MSCs, B), showing
differentiation towards the adipocyte (A.1a - P5, B.1b - P2), osteocyte
(A.2a - P5, B.2b - P2) and chondrocyte (A.3a/4a - P5, B.3b/4b - P2)
lineages, as assessed by Oil Red, Alizarin Red and Toluidine Blue/
Alcian Blue staining, respectively; C. Negative controls, represented
by corresponding pellet-derived MSCs not used in differentiation
assays and stained with Oil Red (C.1c), Alizarin Red (C.2c), Toluidine
blue (C.3c) and Alcian Blue (C.4c); II.A and B. Representative, lower
magnification (10x) images of adipogenic differentiation of WJ
explant (a - P2; b - P5)- and pellet (c - P2; d - P5)-derived MSCs.
MSCs, mesenchymal stem cells; P, passage; WJ, Wharton’s jelly; XF,
xeno-free.
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longing to group B had an increased quantitative mRNA
expression for vWF and CD31 markers (Figure 4.2c and
2d, respectively), as compared to enzymatically dissoci-
ated, freshly isolated WJ cells (P < 0.05) and cells from
group A at a corresponding passage. The gene profile of
cells belonging to groups A and B was further docu-
mented by RT-PCR, showing that only enzymatically
dissociated, freshly isolated WJ cells (P0) and pellet-derived cells belonging to group B expressed CD31,
CD144 and vWF markers involved in endothelial cells
differentiation, proliferation and survival, as well as
GATA2 transcription factor that promotes angiogenesis
[40]; VEGFR1, with a role in stem cell recruitment [41],
chemokine receptors VEGFR2 and/or Tie-2, important
in stem/progenitor cells homing were also shared by
cells belonging to group A and Explant-derived cells be-
longing to group B (Figure 4.3).
Overall, the results of endothelial differentiation assays
indicated that the endothelial differentiation capacity of
WJ-derived adherent cells depended on the cell isolation
method and initial culture conditions.
Discussion
In this study, we report that the use of a selective, XF
culture medium, specifically designed for MSCs, led to
the isolation from human WJ explants and enzymatically
dissociated WJ of cell populations with MSC characteris-
tics as assessed at gene, protein and functional levels,
which were differently expressed according to the cell
isolation method used. Furthermore, we demonstrated
that the initial culture conditions, used for the isolation
and expansion of WJ-MSCs, resulted in lack of subse-
quent endothelial differentiation potential. Therefore,
the use of defined MSC culture media is a prerequisite
for the establishment of the real capacity of WJ-MSCs to
differentiate towards the endothelial lineage.
The WJ-derived cells isolated and expanded in a MSC
XF medium proved to present a robust MSC profile
through expression of CD44/CD73/CD90/CD105 sur-
face markers, multipotent differentiation potential into
adipogenic, osteogenic and chondrogenic cell lineages,
as well as a high proliferation rate. When BM-MSCs
[26,42,43], which expressed less growth-related genes as
compared to WJ-MSCs [44], and adipose stem cells [25]
were manipulated in vitro by using XF media, they pro-
liferated more rapidly than the cells cultured by using
conventional media. In addition, MSCs derived from
enzymatically-digested whole human umbilical cord seg-
ments [45] and umbilical cord matrix [46] had a higher
expansion potential when cultured in serum-free/XF
media, as compared to FBS-based media cultured coun-
terparts and BM-MSCs/adipose stem cells, respectively.
Although we did not compare in this study XF versus
conventional culture media, our results corroborated
with the literature data further indicate that the XF con-
ditions described here might bring an advantage over
the conventional media, in respect of proliferation prop-
erties of WJ-MSCs.
We also demonstrated significant differences in CD44,
CD73 and CD90 surface marker expression in WJ-MSCs
cultured in XF conditions, as well as in WJ-MSCs and
WJ-derived adherent cells exposed to endothelial
Figure 4 (See legend on next page.)
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Figure 4 Gene expression profiles in WJ-derived cells. 1. Aggrecan (a) and osteocalcin (b) quantitative gene expression profiles at P2 and P5 inWJ
explant (E-P2, E-P5)- and pellet (P-P2, P-P5)-derivedMSCs isolated and expanded in the XFmedium, as compared to controls represented byWJ-MSCs at P5
(a) and P2/P5 (b), not employed into differentiation assays; * and **, statistically significant increase in gene expression (P< 0.05), as compared to control and
previous passage, respectively; #, statistically significant decrease in gene expression (P< 0.05), as compared to previous passage; 2.Quantitative vWF (a) and
CD31 (b) gene expression profiles in explant- and pellet-derived cells belonging to group A at P3 and P5 (A-P3, A-P5, C = Controls represented by explant- and
pellet-derivedWJ-MSCs not used into endothelial differentiation assay); Quantitative vWF (c) and CD31 (d) gene expression profiles in explant- and pellet-
derived cells belonging to group B at P3 and P5 (B-P3, B-P5, C = Control represented by enzymatically dissociated, freshly isolatedWJ cells, * = statistically
significant increase in gene expression (P< 0.05) between group B Control (C) and B-P3/B-P5); 3.Qualitative endothelial gene expression profiles inWJ explant-
and pellet-derived cells belonging to groups A and B, after five passages of exposure to endothelial medium, as compared to enzymatically dissociated, freshly
isolatedWJ cells (pellet-P0) and HUVECs. HUVECs, human umbilical vein endothelial cells; MSCs, mesenchymal stem cells; P, passage; vWF, vonWillebrand
factor; WJ, Wharton’s jelly; XF, xeno-free.
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tion method used or the passage number. It is well
known that both in vitro cell manipulation technique
[47] and passage number [48] exert a prominent impact
on the protein expression profile of MSCs. The issue of
heterogeneity in MSC markers expression has also been
reported for BM-MSCs and has been correlated with
their proliferation and differentiation potential [49]. It
has been shown that CD44, CD73 and CD90 markers
were expressed at higher levels in umbilical cord-derived
MSC subpopulations that exhibited a higher prolifera-
tion capacity and a reduced amount of aging cells [50].
In addition, CD44, a cell-surface receptor for hyaluronic
acid, facilitated MSCs migration through interaction
with extracellular hyaluronic acid, suggesting that suchFigure 5 Flow cytometry analysis of WJ explant- and pellet-derived M
(1)- and pellet (2)-derived MSCs at P2; (3) Comparative MFI expression of C
versus P5 (E-P5); (3b) Pellet-derived MSCs at P2 (P-P2) versus P5 (P-P5), as c
commercially available NUFF1 human fibroblast cell line (FIB); (3c) explant-
compared to freshly isolated pellet-derived WJ cells (P-P0). MFI, median flu
Wharton’s jelly; XF, xeno-free.migratory mechanism could be critical for MSCs recruit-
ment to tissue regeneration sites [51]. As CD44 and
CD90 are involved in cell-to-cell interactions, cell adhe-
sion and migration, and CD73 plays an important role in
cell cycle progression and apoptosis, they might differ-
ently control these processes in WJ explant- versus
pellet-derived cells, nevertheless by passage propagation.
Therefore, the biological benefits of such heterogeneity
in the level of surface markers’ expression may be re-
lated to the proposed functions of these cells. Further in-
sights into these markers’ expression by WJ-MSCs
manipulated in XF culture conditions are worthwhile in
order to modulate biological processes, such as cell ad-
hesion, migration and proliferation, to optimize clinical
cell therapy approaches. Thus, the development ofSCs cultured in XF medium. MSC markers expression by WJ explant
D44 and/or CD73 markers in: (3a) Explant-derived MSCs at P2 (E-P2)
ompared to freshly isolated pellet-derived WJ cells (P-P0) and a
derived MSCs at P2 (E-P2) versus pellet-derived MSCs at P2 (P-P2), as
orescence intensity; MSCs, mesenchymal stem cells; P, passage; WJ,
Figure 6 (See legend on next page.)
Corotchi et al. Stem Cell Research & Therapy 2013, 4:81 Page 11 of 16
http://stemcellres.com/content/4/4/81
(See figure on previous page.)
Figure 6 Flow cytometry analysis of WJ-derived cells cultured in endothelial medium after isolation/expansion in different conditions.
A.1 and A.2 - explant- and pellet-derived cells, respectively, belonging to group A, isolated and expanded until P2 in the XF medium, and then
subcultured for five consecutive passages in endothelial medium, showed lack of endothelial surface markers;
B.1 and B.2 - explant- and pellet-derived cells, respectively belonging to group B, isolated and subcultured for five consecutive passages in
endothelial medium, showed differential expression of surface markers: explant-derived cells (B.1) did not gain endothelial surface markers
expression, whereas pellet-derived cells (B.2) exhibited CD31, CD105 and CD144 surface markers expression upon culture into the endothelial
medium; C. Surface markers expression on enzymatically dissociated, freshly isolated WJ cells (pellet-derived P0); D. Comparative MFI expression
of CD44, CD73 and CD90 markers, upon exposure to endothelial differentiation conditions, in: (D.a) explant- versus pellet-derived cells belonging
to group A (A), as compared to enzymatically dissociated, freshly isolated WJ cells (pellet-P0); (D.b) explant-derived cells from group B (B) versus
explant-derived cells from group A (A). MFI, median fluorescence intensity; P, passage; WJ, Wharton’s jelly; XF, xeno-free.
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based also on the expression levels of their surface
markers, may provide improved vectors for the treat-
ment of specific diseases [52].
When assessing multipotent differentiation outcomes,
we demonstrated that in WJ explant- and pellet-derived
MSCs, the chondrogenic and osteogenic differentiation
potential increased and decreased, respectively, by pas-
sage progression. This could be due to the fact that the
MSCs isolation method used (via WJ explants versus en-
zymatic dissociation of WJ) led to the generation of dif-
ferent MSC populations in respect of their multipotent
differentiation capacity. It has also been documented
that the passage number has an important impact on
the differentiation capacity of MSCs [48,53,54] due to a
consistent pattern of changes in the global gene expres-
sion signature of MSCs at different passages [48]. In this
respect, MSCs derived from other sources than WJ, ei-
ther exhibited a decreased osteogenic differentiation
capacity by passage progression [54] or calcium depos-
ition transiently decreased from P4 to P6, but returned
to levels near or above those of primary cells by P10
[55]. Therefore, further work is needed in order to eluci-
date the optimum isolation protocol and passage num-
ber of WJ-MSCs, grown in defined, XF conditions, to
optimize their multipotent differentiation potential
according to the clinical cell therapy foreseen.
Although it has been shown that WJ-MSCs cultured
in conventional media presented a lower adipogenic dif-
ferentiation potential as compared to other MSC
sources, such as the BM [44], periodontal ligament [56]
and chorionic-plate [57], we found that WJ-MSCs iso-
lated and expanded in the XF medium presented differ-
ent degrees of adipogenic differentiation, according to
the isolation method and passage number; interestingly,
the adipogenic differentiation capacity of WJ pellet-
derived MSCs was higher at P5 as compared to P2 and
was inverse proportional with the osteogenic differenti-
ation potential of these cells. This may be due to the in-
volvement of MicroRNA-22 that was found to regulate
adipogenic and osteogenic differentiation of human adi-
pose tissue-derived MSCs in opposite directions [58], afinding that deserves to be further investigated in WJ-
MSCs, too.
While it has been reported that both the osteogenic
gene expression pattern [44] and osteogenic differenti-
ation rate [59] were lower in WJ-MSCs as compared to
BM-MSCs, isolated by using conventional media, we
demonstrated a very robust osteogenic differentiation
potential of WJ explant-derived MSCs, which increased
by passage progression. Furthermore, the influence of
the culture conditions used for MSCs isolation and ex-
pansion on gene and protein expression profile of BM-
MSCs [47], as well as on their osteoblastic differentiation
has been demonstrated. In this regard, XF conditions
used for BM-MSCs culture, through FBS substitution for
allogeneic human platelet lysate, enhanced their osteo-
genic differentiation [43]. Hence, the WJ-MSCs isolated
and expanded by using the selective, XF conditions
described here might be better cell candidates for bone
regeneration, as compared to WJ-MSCs manipulated
in conventional media, suggesting potential superior
in vivo osteogenic regeneration outcomes. In respect of
the impact of the XF conditions on chondrogenic dif-
ferentiation potential, it has been shown that BM-
MSCs that were isolated, stored and expanded using
XF materials, including the XF medium used in our
study, had a higher gene expression of aggrecan than
cells cultured in conventional media [42]. These obser-
vations indicate that WJ-MSCs, manipulated in vitro by
using XF media, might also represent superior cell can-
didates for cartilage repair.
Upon exposure to endothelial differentiation signals,
we showed that both WJ explant- and pellet-derived
cells from Group A - isolated and expanded until P2
in MSC XF medium, and then subcultured for five pas-
sages in endothelial differentiation conditions - did not
exhibit endothelial differentiation potential. By contrast,
pellet- but not explant-derived cells belonging to Group
B - isolated and expanded in endothelial differentiation
conditions from P0 to P5 - presented endothelial cell
characteristics, being different in respect to surface and
gene marker expression, as well as functional properties.
This might be due to the fact that the enzymatically
Figure 7 Morphology (I) and tube formation capacity (II) ofWJ-
derived cells used into endothelial differentiation assays. A – Group
A cells isolated and expanded until P2 in the XF medium, and then
subcultured for five consecutive passages in endothelial medium;
B – Group B cells isolated and subcultured for five consecutive
passages in endothelial medium. Explant- and pellet-derived cells
belonging to group A did not show morphological (I.A – 1a/1b and
3a/3b, respectively) and functional (II.A – 1 and 4, respectively)
features of endothelial cells. Within group B, explant-derived cells
also neither exhibited morphological (I.B – 2a/2b), nor functional
(II.B – 2) characteristics of endothelial cells, whereas pellet-derived
cells presented endothelial characteristics both at morphological
(I.B – 4a/4b) and functional (II.B – 5a/5b) levels; II.B – 3, positive control
for Matrigel tube formation assay, represented by a commercially
available HUVEC line. Higher magnifications of corresponding
pictures are pointed by arrows. HUVEC, human umbilical vein
endothelial cell; MSCs, mesenchymal stem cells; P, passage; WJ,
Wharton’s jelly; XF, xeno-free.
Corotchi et al. Stem Cell Research & Therapy 2013, 4:81 Page 13 of 16
http://stemcellres.com/content/4/4/81dissociated, freshly isolated WJ cell populations
contained stem/progenitor cells or other contaminating
endothelial cell types able to give rise to an endothelial
progeny, when seeded directly into endothelium medium
for five passages; in the case of explant-derived cells of
group B, these cells may not migrate out of the explants.
Furthermore, they may be lost when initially cultured in
XF conditions.
Interestingly, we also demonstrated that, besides the
endothelial markers expression at gene and protein
levels, the WJ pellet-derived cells belonging to group B
presented CD73 and CD44 MSC surface markers. Al-
though there are no data yet documenting CD44 marker
expression on endothelial cell outgrowth derived from
WJ, it has been reported the involvement of CD44 mol-
ecule in endothelial cell proliferation, migration and
angiogenesis [60], contributing to the organization and/
or stability of developing endothelial tubular networks
[61]. While there is also no evidence of CD73 expression
on endothelial progenitors derived from any adult tis-
sues, Choi KD et al. [62] identified a novel population of
CD73+ endothelial progenitors derived from human em-
bryonic stem cells. These data and the fact that the um-
bilical cord is closer in development to embryonic than
adult tissues [44,57], reinforce the speculation that the
isolated endothelial progeny within pellet-derived cells
belonging to group B resulted from a different stem/pro-
genitor cell type than MSCs, residing in the matrix of
the umbilical cord, whose isolation might have been fa-
cilitated by the use of enzymatic dissociation and initial
endothelial culture conditions.
Although some reports have demonstrated endothelial
differentiation of WJ-derived cells in vitro or in vivo
[13,16-19], endothelial differentiation of WJ-MSCs is still
very controversial. Furthermore, it has been shown that
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and adipose tissue, did not display functional properties
of endothelial cells, but promoted neovascularization via
paracrine mechanisms [63,64]. Choi M et al. [65] also
demonstrated the lack of endothelial differentiation
capacity of WJ-MSCs, isolated and expanded in a con-
ventional FBS-based medium, but paying careful atten-
tion to the removal of the umbilical cord blood vessels
and amnion. Upon exposure to endothelial differenti-
ation media, these WJ-MSCs neither expressed endothe-
lial markers, nor directly participated to angiogenesis/
vasculogenesis in vitro and in vivo; rather, the cells im-
proved perfusion recovery and neovascularization by
secreting paracrine factors and by functioning as peri-
vascular precursor cells [65]. Our data, corroborated to
this report, suggest that the MSCs’ isolation method has
a tremendous impact on the homogeneity of the cells
and their true endothelial differentiation capacity. By
contrast with other authors that did not use a selective
MSC medium for WJ-MSCs isolation prior to their ex-
posure to endothelial differentiation conditions [65] or
cultured freshly isolated cells directly in endothelial dif-
ferentiation media [17], we further documented, by
using a defined, XF medium for MSCs, that the initial
culture conditions have a strong impact on the progeny
outgrowth resulted upon exposure of WJ-MSCs to endo-
thelial differentiation signals. Based on our observations,
we speculate that in the case of previous reports, de-
scribing WJ-MSCs differentiation into endothelial phe-
notypes, the endothelial outgrowth was derived from
other types of stem cells than WJ-MSCs, circulating
endothelial progenitors, or umbilical vein endothelial
cells, contaminating the primary cultures during the dis-
section process, performed to remove the umbilical cord
arteries and the vein.
It is well known that gene expression profiling is sig-
nificantly different among MSCs from distinct sources
and that intrinsic gene expression has an important im-
pact on MSCs overall differentiation potential [66]. It
has been postulated that BM-MSCs constitutively
expressed genes related to immunomodulation, adipose
tissue derived-MSCs highly expressed genes implicated
in tissue development [14], whereas the transcriptome
profiling of WJ-MSCs revealed an increased expression
of genes involved in liver development [66] and an in-
herent bias towards the neuro-ectoderm lineage [14,67].
These observations suggest that WJ-MSCs might be bet-
ter cell candidates for differentiation into hepatocyte and
neuronal rather than endothelial phenotypes. As MSCs
from different sources exhibit distinct and unique gene
expression signatures, which make them competent to
give rise to specific lineages rather than others [14], at
this moment there are no well-defined master MSCs
that are suitable for vascular regeneration. Therefore,according to the isolation and culture methods used,
MSCs should be rigorously characterized, especially at
the gene and functional levels, and much caution needs
to be given when choosing the best MSC type for a par-
ticular therapeutic application.
Conclusions
Taken together, our data indicate that the isolation
method and XF culture conditions influence the
multipotent differentiation capacity of human WJ-MSCs.
The use of a selective, XF medium for MSCs led to the
isolation and expansion of MSC populations from the
matrix of the umbilical cord, free of contamination with
other stem, progenitor or adult cell types that may be
misleading concerning the real endothelial differenti-
ation potential of WJ-MSCs. Therefore, the availability
of optimized in vitro assays, involving ready-to-use XF
media for human WJ-MSCs manipulation, might have a
substantial scientific and clinical potential. Thus, a prior-
ity in the field should be the standardization of isolation
and culture expansion techniques in defined, XF media
for an accurate characterization of WJ-MSCs, as candi-
dates for clinical cell therapy applications.
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